Showing results (41-50 of 58) with videos related to
Sort By:
Pageof 6
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|August 1, 1992
Bryostatin 1 activates T cells that have antitumor activityT M Tuttle, T H Inge, C P Wirt, et al.Cancer Research|February 1, 1992
Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1T M Tuttle, T H Inge, K P Bethke, et al.Leukemia|July 1, 1996
Effect of AS101 on bryostatin 1-mediated differentiation induction, cell cycle arrest, and modulation of drug-induced apoptosis in human myeloid leukemia cellsA S Rao, A J Freemerman, W D Jarvis, et al.Cancer Gene Therapy|September 20, 2014
Expansion of melanoma-specific lymphocytes in alternate gamma chain cytokines: gene expression variances between T cells and T-cell subsets exposed to IL-2 versus IL-7/15C K Zoon, E Seitelman, S Keller, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1995
Adoptive transfer of bryostatin-activated tumor-sensitized lymphocytes prevents or destroys tumor metastases without expansion in vitroM D Fleming, H D Bear, K Lipshy, et al.Annals of Surgery|June 11, 1992
Formal hepatic resection of colorectal liver metastases. Ploidy and prognosisD S Lind, G A Parker, J S Horsley, et al.American Journal of Surgery|April 1, 1989
Treatment of biliary obstruction caused by metastatic cancerH D Bear, M A Turner, G A Parker, et al.Annals of Surgery|March 1, 1989
Management of biliary obstruction in patients with unresectable carcinoma of the pancreasP C McGrath, P M McNeill, J P Neifeld, et al.Annals of Surgical Oncology|May 1, 1996
Complications of mastectomy and their relationship to biopsy techniqueK A Lipshy, J P Neifeld, R M Boyle, et al.American Journal of Clinical Oncology|October 1, 1994
The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel ProjectE P Mamounas, S Anderson, D L Wickerham, et al.Pageof 6